Cargando…

Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study

BACKGROUND: Multiple clinical trials demonstrate consistent but modest benefit of adjuvant extended endocrine therapy (EET) in HR + breast cancer patients. Predictive biomarkers to identify patients that benefit from EET are critical to balance modest reductions in risk against potential side effect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sgroi, Dennis C., Treuner, Kai, Zhang, Yi, Piper, Tammy, Salunga, Ranelle, Ahmed, Ikhlaaq, Doos, Lucy, Thornber, Sarah, Taylor, Karen J., Brachtel, Elena, Pirrie, Sarah, Schnabel, Catherine A., Rea, Daniel, Bartlett, John M. S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9758861/ https://www.ncbi.nlm.nih.gov/pubmed/36527133 http://dx.doi.org/10.1186/s13058-022-01589-x

Ejemplares similares

Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study
por: Bartlett, John M.S., et al.
Publicado: (2022)

Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen—To Offer More? (aTTom) trial
por: Bartlett, J M S, et al.
Publicado: (2019)

ACK1–AR and AR–HOXB13 signaling axes: epigenetic regulation of lethal prostate cancers
por: Kim, Eric H, et al.
Publicado: (2020)

IL-1-conferred gene expression pattern in ERα(+) BCa and AR(+) PCa cells is intrinsic to ERα(−) BCa and AR(−) PCa cells and promotes cell survival
por: Nawas, Afshan F., et al.
Publicado: (2020)

β-AR Blockers Suppresses ER Stress in Cardiac Hypertrophy and Heart Failure
por: Ni, Li, et al.
Publicado: (2011)

Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer?
por: Bronte, Giuseppe, et al.
Publicado: (2019)

The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines
por: Subik, Kristina, et al.
Publicado: (2010)

AR/ER Ratio Correlates with Expression of Proliferation Markers and with Distinct Subset of Breast Tumors
por: Rangel, Nelson, et al.
Publicado: (2020)

$^{43}$Ar and $^{44}$Ar
por: Hudis, J, et al.
Publicado: (1970)

$^{43}Ar$ and $^{44}Ar$
por: Hudis, J, et al.
Publicado: (1970)

To Be(Ar) Or Not to Be(Ar) – Jones Dilemma?
por: Andrews, Nicholas A., et al.
Publicado: (2022)

Re-Expression of ERα and AR in Receptor Negative Endocrine Cancers via GSK3 Inhibition
por: Sharma, Vikas, et al.
Publicado: (2022)

Immunoreactivities of AR, ERα, ERβ and aromatase in the nuptial pad of Chinese brown frog (Rana dybowskii) during pre-hibernation and the breeding period
por: Tang, Zeqi, et al.
Publicado: (2021)

Diverse roles of androgen receptor (AR) domains in AR-mediated signaling
por: Claessens, Frank, et al.
Publicado: (2008)

The expression status of TRX, AR, and cyclin D1 correlates with clinicopathological characteristics and ER status in breast cancer
por: Huang, Weisun, et al.
Publicado: (2016)

ER/AR Multi-Conformational Docking Server: A Tool for Discovering and Studying Estrogen and Androgen Receptor Modulators
por: Wang, Feng, et al.
Publicado: (2022)

Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer
por: Wüstmann, Neele, et al.
Publicado: (2023)

On atmospheric $^{39}Ar$ and $^{42}Ar$ abundance
por: Cennini, P, et al.
Publicado: (1995)

The MYC axis in advanced prostate cancer is impacted through concurrent targeting of ERβ and AR using a novel ERβ-selective ligand alongside Enzalutamide
por: Gray, Jaimie S., et al.
Publicado: (2023)

FOXA1 and AR in invasive breast cancer: new findings on their co-expression and impact on prognosis in ER-positive patients
por: Rangel, Nelson, et al.
Publicado: (2018)

Digital Validation of Breast Biomarkers (ER, PR, AR and HER2) in Cytology Specimens Using Three Different Scanners
por: Salama, Abeer M., et al.
Publicado: (2021)

Ár njöt'i ar hai = El color de la tierra
Publicado: (2014)

The mass of $^{32}Ar$ and $^{33}Ar$ for fundamental tests
por: Blaum, K, et al.
Publicado: (2003)

Masses of 32Ar and 33Ar for fundamental tests
por: Blaum, K, et al.
Publicado: (2003)

AR Splicing Variants and Resistance to AR Targeting Agents
por: Kanayama, Mayuko, et al.
Publicado: (2021)

Determination of $^{44}Ar$(n,$\gamma$)$^{45}$Ar, and $^{46}$Ar(n,$\gamma$)$^{47}$Ar reaction rates by (d,p) transfer reactions
por: Sorlin, O, et al.
Publicado: (2002)

MEIS1 down-regulation by MYC mediates prostate cancer development through elevated HOXB13 expression and AR activity
por: Whitlock, Nichelle C., et al.
Publicado: (2020)

ARS Leptogenesis
por: Drewes, M., et al.
Publicado: (2017)

Ars melancholiae
por: Weiss, Silvius Leopold, 1686-1750
Publicado: (1994)

Ars Obstetrica
por: Armytage, V. B. Green
Publicado: (1930)

Ars Gynæcologica
por: Green-Armytage, V. B.
Publicado: (1930)

Ars Obstetrica
por: Umachigi, V. S.
Publicado: (1930)

Ars Longa
Publicado: (1893)

Boutique neutrons advance (40)Ar/(39)Ar geochronology
por: Rutte, Daniel, et al.
Publicado: (2019)

Identification of AR-V7 downstream genes commonly targeted by AR/AR-V7 and specifically targeted by AR-V7 in castration resistant prostate cancer
por: Sugiura, Masahiro, et al.
Publicado: (2020)

Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer
por: Narayanan, Ramesh
Publicado: (2020)

GABARAPL1 Promotes AR+ Prostate Cancer Growth by Increasing FL-AR/AR-V Transcription Activity and Nuclear Translocation
por: Su, Bing, et al.
Publicado: (2019)

Ars medica mexicana
por: Pérez-Tamayo, Ruy

The decay of $^{31}$Ar
por: García-Borge, M J, et al.
Publicado: (1990)

Pelagonius, Ars Veterinaria
por: Nutton, Vivian
Publicado: (1982)

Cannot write session to /tmp/vufind_sessions/sess_r0va0edtkcj9mclotpflrv1rqe